Previous 10 | Next 10 |
NeuroBo Pharmaceuticals (NASDAQ: NRBO ): Q1 GAAP EPS of -$0.30 misses by $0.20 . More news on: NeuroBo Pharmaceuticals, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
BOSTON , May 20, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial...
BOSTON , April 21, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that...
BOSTON , April 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has ...
Gainers: NeuroMetrix (NASDAQ: NURO ) +147% . More news on: NeuroMetrix, Inc., Sonnet BioTherapeutics Holdings, Inc., Neovasc Inc., Stocks on the move, , Read more ...
NeuroBo Pharmaceuticals ( NRBO -36.9% ) has entered into a definitive agreement for the purchase and sale in a registered direct offering of 750,000 common shares, at a purchase price of $10.00 per share, for gross proceeds of $7.5M. More news on: NeuroBo Pharmaceuticals, Inc., He...
BOSTON , April 14, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it...
NeuroBo Pharmaceuticals (NASDAQ: NRBO ): FY GAAP EPS of -$4.08. More news on: NeuroBo Pharmaceuticals, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
BOSTON , March 30, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financi...
Gainers: Bellerophon Therapeutics (NASDAQ: BLPH ) +144% . More news on: Bellerophon Therapeutics, Inc., Brickell Biotech, Inc., Wanda Sports Group Company Limited, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...